Gut microbiota–host immunity crosstalk in psoriasis: from dysbiosis to cutaneous inflammation
- 1Department of Dermatology, Affiliated Hospital of Hebei University
- 2Department of General Surgery, Affiliated Hospital of Hebei University
Abstract
Psoriasis is a chronic inflammatory skin disease driven by the IL-23/IL-17 axis. Evidence accumulated over the past decade indicates that its pathogenesis extends beyond the skin and involves bidirectional communication between the intestinal microbiota and host immunity. This narrative review organizes current evidence along a proposed sequence running from gut dysbiosis and intestinal barrier damage, through altered microbial metabolites, to reprogrammed host immune responses and cutaneous inflammation. We summarize the gut microbiota changes reported in patients with psoriasis and the clinical evidence for impaired intestinal permeability. We describe how microbiota-derived metabolites—short-chain fatty acids (SCFAs), tryptophan/kynurenine metabolites, and bile acids—modulate Th17/Treg balance and innate immunity through the aryl hydrocarbon receptor (AhR) and G protein-coupled receptors. We then review clinical data on microbiome-directed interventions, chiefly probiotics and fecal microbiota transplantation (FMT), and close with the outstanding issues in causal inference, methodological heterogeneity, and standardization of interventions. The current evidence is consistent with the gut–skin axis hypothesis. The direction of causality between the microbiota and psoriasis, the dose-response relationship, and the clinical benefit of microbiome-directed therapy nonetheless remain to be confirmed in prospective cohorts and well-designed randomized controlled trials.
Related
- Gut microbiota in type 2 diabetes mellitus: mechanistic links between dysbiosis, insulin resistance, and chronic low-grade inflammation
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
- From Dysbiosis to Disease: How Vaginal Microbiota Shape Group B Streptococcus Pathogenesis
- The Oral–Gut–Systemic Axis in Periodontitis: Microbiome Dysbiosis, Immune Crosstalk and Translational Perspectives
- Endothelial Dysfunction in Psoriasis: A Comparative Analysis of Cutaneous, Inflammatory, and Metabolic Correlates
BibTeX
@article{zhang2026microbiotahost,
title = {{Gut microbiota–host immunity crosstalk in psoriasis: from dysbiosis to cutaneous inflammation}},
author = {Meng Zhang and Shengni Zhang and Xiangxiang Ren},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1957850},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1957850/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiota–host immunity crosstalk in psoriasis: from dysbiosis to cutaneous inflammation
AU - Meng Zhang
AU - Shengni Zhang
AU - Xiangxiang Ren
PY - 2026
DA - 2026/10/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1957850
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1957850/full
AB - Psoriasis is a chronic inflammatory skin disease driven by the IL-23/IL-17 axis. Evidence accumulated over the past decade indicates that its pathogenesis extends beyond the skin and involves bidirectional communication between the intestinal microbiota and host immunity. This narrative review organizes current evidence along a proposed sequence running from gut dysbiosis and intestinal barrier damage, through altered microbial metabolites, to reprogrammed host immune responses and cutaneous inflammation. We summarize the gut microbiota changes reported in patients with psoriasis and the clinical evidence for impaired intestinal permeability. We describe how microbiota-derived metabolites—short-chain fatty acids (SCFAs), tryptophan/kynurenine metabolites, and bile acids—modulate Th17/Treg balance and innate immunity through the aryl hydrocarbon receptor (AhR) and G protein-coupled receptors. We then review clinical data on microbiome-directed interventions, chiefly probiotics and fecal microbiota transplantation (FMT), and close with the outstanding issues in causal inference, methodological heterogeneity, and standardization of interventions. The current evidence is consistent with the gut–skin axis hypothesis. The direction of causality between the microbiota and psoriasis, the dose-response relationship, and the clinical benefit of microbiome-directed therapy nonetheless remain to be confirmed in prospective cohorts and well-designed randomized controlled trials.
SN - 1664-3224
ER -